Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
B Cell Activation and Differentiation01:24

B Cell Activation and Differentiation

The adaptive immune response, a sophisticated defense mechanism, relies on the activation and differentiation of B lymphocytes, or B cells. These processes enable our bodies to mount a tailored response against specific pathogens such as bacteria, free virus particles, toxins, and parasites.
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum: Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Lenalidomide Plus Rituximab for Relapsed/Refractory Indolent Non-Hodgkin Lymphoma: 5-Year Follow-Up and Subgroup Analyses From the Phase III AUGMENT Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

MutAnt: mutation annotation tool predicts deleteriousness of missense mutations and improves mutation calling from transcriptomics.

Human genetics·2025
Same author

Mutational and copy number analysis at diagnosis and relapse of mantle cell lymphoma.

Haematologica·2025
Same author

AI-driven multimodal algorithm predicts immunotherapy and targeted therapy outcomes in clear cell renal cell carcinoma.

Cell reports. Medicine·2025
Same author

Integrative genomic analysis of DLBCL identifies immune environments associated with bispecific antibody response.

Blood·2025

Related Experiment Video

Updated: May 11, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Developing novel strategies to target B-cell malignancies.

Nathan Fowler1, Yasuhiro Oki

  • 1From the Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.

American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|May 30, 2013
PubMed
Summary

New targeted therapies are shifting cancer treatment away from traditional chemotherapy. These agents focus on specific pathways driving B-cell malignancies, showing promise in clinical trials for lymphoma and leukemia.

More Related Videos

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: May 11, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
12:16

A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells

Published on: October 16, 2018

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Key pathways driving malignant B-cell development have been identified.
  • The role of the immune microenvironment in tumor progression and treatment resistance is increasingly understood.
  • Advances in medicinal chemistry and structure-based drug design are enabling targeted therapies.

Purpose of the Study:

  • To review novel non-antibody-based targeted agents in development for B-cell malignancies.
  • To discuss the specific cellular pathways targeted by these agents.
  • To summarize their activity in various B-cell malignancies.

Main Methods:

  • Review of current literature on targeted agents in early clinical development.
  • Focus on non-antibody-based therapies targeting key cellular pathways.
  • Analysis of clinical activity data in lymphoma and leukemia subtypes.

Main Results:

  • Several targeted agents are in early clinical development, demonstrating activity in B-cell malignancies.
  • Target pathways include B-cell receptor signaling, PI3K/mTOR/AKT, HDAC, apoptosis regulators (BCL-2 family), proteasome, and cell-cell interactions.
  • Monoclonal antibodies targeting CD19, CD22, CD37, and CD20 also show promise in relapsed B-cell malignancies.

Conclusions:

  • A shift towards targeted agents over traditional chemotherapy is evident in B-cell malignancy treatment.
  • Novel targeted therapies are showing significant promise in clinical trials.
  • Further research and development are crucial for optimizing these treatments.